RespireRx Pharmaceuticals Inc. Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development
December 18, 2017 08:45 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 18, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that a paper detailing the neurobiologic safety...